Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: pluripotent stem cell therapies - VistaGen

Drug Profile

Research programme: pluripotent stem cell therapies - VistaGen

Latest Information Update: 13 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VistaGen Therapeutics
  • Developer Duke University; VistaGen Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Diabetes mellitus; Heart failure; Metabolic disorders

Most Recent Events

  • 11 Jun 2018 VistaGen Therapeutics has patent protection for pluripotent stem cell therapies in Japan
  • 23 May 2018 VistaGen Therapeutics receives patent allowance for pluripotent stem cell-derived chondrocytes, chondrocyte lineage cells, cartilage-like tissue and cartilage in USA
  • 08 Nov 2017 VistaGen Therapeutics has patent protection for methods of production of haematopoietic precursor stem cells in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top